AI in Clinical Trials Market by Function, Phase, Indication, Tool, End-User & Region - Global Forecast to 2030

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 SEGMENTS CONSIDERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key sources for secondary data
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key sources for primary data
    • 2.1.2.2 Objectives of primary research
    • 2.1.2.3 Key data from primary sources
    • 2.1.2.4 Key insights from primary experts
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 SUPPLY-SIDE REVENUE SHARE ANALYSIS
  • 2.2.2 PARENT MARKET APPROACH
  • 2.2.3 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS
  • 2.2.4 MARKET SEGMENT ASSESSMENT
  • 2.2.5 GEOGRAPHIC MARKET ASSESSMENT
• 2.3 DATA TRIANGULATION
• 2.4 MARKET SHARE ESTIMATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
  • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.6.2 SCOPE-RELATED LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 AI IN CLINICAL TRIALS MARKET OVERVIEW
• 4.2 AI IN CLINICAL TRIALS MARKET, BY REGION
• 4.3 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY END USER AND COUNTRY
• 4.4 AI IN CLINICAL TRIALS MARKET: GEOGRAPHICAL SNAPSHOT
• 4.5 AI IN CLINICAL TRIALS MARKET: DEVELOPED VS. EMERGING MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
• 5.3 MARKET DYNAMICS
  • 5.3.1 DRIVERS
    • 5.3.1.1 Increasing demand for personalized treatments
    • 5.3.1.2 Support for decentralized and global trials
    • 5.3.1.3 Regulatory compliance and ethical considerations
    • 5.3.1.4 Automated document review for better regulatory compliance
    • 5.3.1.5 Focus on real-time data management and analysis
  • 5.3.2 RESTRAINTS
    • 5.3.2.1 Data privacy and security concerns
    • 5.3.2.2 Integration challenges with legacy systems and resistance from healthcare professionals
    • 5.3.2.3 High implementation cost and need for skilled AI professionals
  • 5.3.3 OPPORTUNITIES
    • 5.3.3.1 Use of predictive analytics in clinical trials
    • 5.3.3.2 Development of virtual control arms for faster trials
    • 5.3.3.3 Integrating natural language processing into clinical trials for data extraction
  • 5.3.4 CHALLENGES
    • 5.3.4.1 Addressing algorithm bias and fairness
    • 5.3.4.2 Insufficient technical expertise in AI-based solutions
• 5.4 INDUSTRY TRENDS
  • 5.4.1 INCREASING ADOPTION OF DECENTRALIZED CLINICAL TRIALS
  • 5.4.2 RISING FOCUS ON AI-POWERED PATIENT RECRUITMENT AND RETENTION
• 5.5 ECOSYSTEM ANALYSIS
• 5.6 CASE STUDY ANALYSIS
  • 5.6.1 AI-POWERED APPROACH TO OVERCOME CHALLENGES IN IPF DRUG DEVELOPMENT
  • 5.6.2 REVOLUTIONIZING CLINICAL TRIAL ENROLLMENT WITH ADVANCED MATCHING NETWORKS
  • 5.6.3 BREAKTHROUGH IN CANCER TREATMENT WITH FDA APPROVAL FOR PHASE 1 TRIALS
• 5.7 VALUE CHAIN ANALYSIS
• 5.8 PORTER'S FIVE FORCES ANALYSIS
  • 5.8.1 BARGAINING POWER OF SUPPLIERS
  • 5.8.2 BARGAINING POWER OF BUYERS
  • 5.8.3 THREAT OF SUBSTITUTES
  • 5.8.4 THREAT OF NEW ENTRANTS
  • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.9 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.9.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.9.2 KEY BUYING CRITERIA
• 5.10 REGULATORY LANDSCAPE
  • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10.2 REGULATORY FRAMEWORK
• 5.11 PATENT ANALYSIS
  • 5.11.1 PATENT PUBLICATION TRENDS FOR AI IN CLINICAL TRIALS
  • 5.11.2 JURISDICTION AND TOP APPLICANT ANALYSIS
• 5.12 TECHNOLOGY ANALYSIS
  • 5.12.1 KEY TECHNOLOGIES
    • 5.12.1.1 Machine learning
    • 5.12.1.2 Natural language processing
    • 5.12.1.3 Computer vision
  • 5.12.2 COMPLEMENTARY TECHNOLOGIES
    • 5.12.2.1 Internet of things
    • 5.12.2.2 Cloud computing
  • 5.12.3 ADJACENT TECHNOLOGIES
    • 5.12.3.1 Advanced genomics
• 5.13 PRICING ANALYSIS
  • 5.13.1 INDICATIVE PRICE OF KEY AI SOFTWARE, BY KEY PLAYER, 2023
  • 5.13.2 INDICATIVE PRICE TREND OF KEY AI SOFTWARE, BY REGION, 2022-2024
• 5.14 KEY CONFERENCES & EVENTS, 2024-2025
• 5.15 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
• 5.16 UNMET NEEDS AND END-USER EXPECTATIONS
  • 5.16.1 UNMET NEEDS
  • 5.16.2 END-USER EXPECTATIONS
• 5.17 INVESTMENT & FUNDING SCENARIO
• 5.18 IMPACT OF AI/GEN AI ON AI IN CLINICAL TRIALS MARKET
  • 5.18.1 KEY USE CASES
  • 5.18.2 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
    • 5.18.2.1 Case study
    • 5.18.2.2 Clinical trials market
    • 5.18.2.3 eClinical solutions market
    • 5.18.2.4 AI in biotechnology market
  • 5.18.3 USERS READINESS AND IMPACT ASSESSMENT
    • 5.18.3.1 User readiness
      • 5.18.3.1.1 Pharmaceutical & biopharmaceutical companies
      • 5.18.3.1.2 Contract research organizations
    • 5.18.3.2 Impact assessment
      • 5.18.3.2.1 User A: Healthcare providers
      • 5.18.3.2.2 User B: Research institutes & laboratories

6 AI IN CLINICAL TRIALS MARKET, BY OFFERING

• 6.1 INTRODUCTION
• 6.2 END-TO-END SOLUTIONS
  • 6.2.1 COST-EFFECTIVENESS, IMPROVED EFFICIENCY, AND REDUCED HUMAN ERRORS TO DRIVE ADOPTION IN CLINICAL TRIALS
• 6.3 NICHE SOLUTIONS
  • 6.3.1 HIGH FAILURE RATES OF CLINICAL TRIALS AND NEED FOR STREAMLINED PROCESSES TO FUEL MARKET GROWTH
• 6.4 TECHNOLOGY PROVIDERS
  • 6.4.1 NEED TO ACCELERATE DRUG DEVELOPMENT PROCESSES AND HIGH DEMAND FOR PERSONALIZED MEDICINES TO AID MARKET GROWTH
• 6.5 SERVICES
  • 6.5.1 CONSULTING SERVICES
    • 6.5.1.1 Consulting services to optimize trial design, enhance patient recruitment, and improve data management
  • 6.5.2 IMPLEMENTATION SERVICES & ONGOING IT SUPPORT
    • 6.5.2.1 Need for smooth integration and optimization of AI technologies to boost segment growth
  • 6.5.3 TRAINING & EDUCATION SERVICES
    • 6.5.3.1 Need for skilled talent for managing complex AI systems to augment segment growth
  • 6.5.4 POST-SALES & MAINTENANCE SERVICES
    • 6.5.4.1 Development of complex AI systems and need for continuous improvement in AI algorithms to drive segment growth

7 AI IN CLINICAL TRIALS MARKET, BY FUNCTION

• 7.1 INTRODUCTION
• 7.2 PATIENT RECRUITMENT
  • 7.2.1 PATIENT IDENTIFICATION & SCREENING
    • 7.2.1.1 Reduced patient screening time and better accuracy than human clinicians to drive market
  • 7.2.2 PATIENT ENGAGEMENT & RETENTION
    • 7.2.2.1 Better personalized communication and support for clinical trials to propel market growth
  • 7.2.3 SITE OPTIMIZATION
    • 7.2.3.1 Cost-effective and improved participant recruitment and retention to fuel segment growth
• 7.3 TRIAL DESIGN OPTIMIZATION
  • 7.3.1 WORKFLOW MANAGEMENT
    • 7.3.1.1 Effective real-time tracking, automated reporting, and milestone monitoring to spur segment growth
  • 7.3.2 PREDICTIVE MODELING
    • 7.3.2.1 Ability to optimize trial design, predict risks, and identify effective treatment protocols to drive segment
  • 7.3.3 RISK MANAGEMENT
    • 7.3.3.1 AI-driven solutions for risk prediction to improve patient safety and data integrity
• 7.4 DATA MANAGEMENT & QUALITY CONTROL
  • 7.4.1 FOCUS ON MAINTAINING DATA ACCURACY AND INTEGRITY IN CLINICAL TRIALS TO BOOST ADOPTION
• 7.5 ADVERSE EVENT PREDICTION & DETECTION
  • 7.5.1 MITIGATING RISKS AND HARNESSING AI-DRIVEN ADVERSE EVENT DETECTION TO SPUR MARKET GROWTH
• 7.6 DRUG REPURPOSING
  • 7.6.1 DRUG REPURPOSING TO VALIDATE HYPOTHESES AGAINST REAL-TIME PATIENT DATA IN RARE DISEASES
• 7.7 REGULATORY COMPLIANCE
  • 7.7.1 COMPLEXITY OF GLOBAL REGULATORY ENVIRONMENTS AND NEED FOR FASTER DRUG APPROVALS TO AID MARKET GROWTH

8 AI IN CLINICAL TRIALS MARKET, BY PHASE

• 8.1 INTRODUCTION
• 8.2 PHASE I CLINICAL TRIALS
  • 8.2.1 FASTER PATIENT IDENTIFICATION AND RECRUITMENT TO PROPEL ADOPTION OF AI
• 8.3 PHASE II CLINICAL TRIALS
  • 8.3.1 NEED FOR ACCURATE PREDICTION OF OPTIMAL DOSAGE IN PHASE II TRIALS TO BOOST USE OF AI
• 8.4 PHASE III CLINICAL TRIALS
  • 8.4.1 NEED TO CHECK DRUG EFFICACY AND MONITOR ADVERSE REACTIONS TO AUGMENT MARKET GROWTH
• 8.5 PHASE IV CLINICAL TRIALS
  • 8.5.1 AI TO ASSESS SAFETY AND LONG-TERM OUTCOMES OF TREATMENT IN LARGER PATIENT POPULATION UNDER PHASE IV TRIALS

9 AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE

• 9.1 INTRODUCTION
• 9.2 CLOUD-BASED SOLUTIONS
  • 9.2.1 PUBLIC CLOUD-BASED SOLUTIONS
    • 9.2.1.1 Reduced need for costly on-premises infrastructure and better regulatory compliance to fuel adoption
  • 9.2.2 PRIVATE CLOUD-BASED SOLUTIONS
    • 9.2.2.1 Better security and personalization for sensitive data to propel segment growth
  • 9.2.3 MULTI CLOUD-BASED SOLUTIONS
    • 9.2.3.1 Use of advanced predictive modeling for patient recruitment and site performance optimization to drive market
  • 9.2.4 HYBRID CLOUD-BASED SOLUTIONS
    • 9.2.4.1 Better flexibility in data management to reduce resource requirements in clinical trials
• 9.3 ON-PREMISES SOLUTIONS
  • 9.3.1 ON-PREMISES SOLUTIONS TO OFFER SECURE ENVIRONMENT FOR MANAGING SENSITIVE DATA AND RUNNING COMPLEX ALGORITHMS

10 AI IN CLINICAL TRIALS MARKET, BY INDICATION

• 10.1 INTRODUCTION
• 10.2 ONCOLOGY
  • 10.2.1 HIGH PREVALENCE OF CANCER AND SHORTAGE OF EFFECTIVE DRUGS TO DRIVE SEGMENT GROWTH
• 10.3 NEUROLOGICAL DISEASES
  • 10.3.1 COMPLEXITY OF NEUROGENERATIVE DISORDERS AND SHORTAGE OF DRUGS FOR PARKINSON'S DISEASE TO SPUR MARKET GROWTH
• 10.4 CARDIOVASCULAR DISEASES
  • 10.4.1 RISING DEMAND FOR NOVEL CARDIOVASCULAR DRUGS TO DRIVE SEGMENT
• 10.5 METABOLIC DISEASES
  • 10.5.1 RISING PREVALENCE OF DIABETES AND OBESITY TO SUPPORT MARKET GROWTH
• 10.6 INFECTIOUS DISEASES
  • 10.6.1 RECENT EPIDEMIC OUTBREAKS TO BOOST DRUG DISCOVERY ACTIVITIES FOR INFECTIOUS DISEASES
• 10.7 IMMUNOLOGY DISEASES
  • 10.7.1 GROWING DRUG PIPELINE FOR IMMUNOLOGICAL DISORDERS TO FAVOR MARKET GROWTH
• 10.8 OTHER DISEASES

11 AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY

• 11.1 INTRODUCTION
• 11.2 MACHINE LEARNING
  • 11.2.1 DEEP LEARNING
    • 11.2.1.1 Reduced chance of errors in clinical trials and enhanced data consistency to augment segment growth
  • 11.2.2 SUPERVISED LEARNING
    • 11.2.2.1 Supervised learning to focus on effective patient stratification, disease progression prediction, and biomarker identification
  • 11.2.3 UNSUPERVISED LEARNING
    • 11.2.3.1 Effective handling of complex and unstructured datasets to aid adoption in trial design and execution
  • 11.2.4 REINFORCEMENT LEARNING
    • 11.2.4.1 Dynamic learning capabilities to aid adoption in personalized medicine and precision oncology
  • 11.2.5 OTHER MACHINE LEARNING TECHNOLOGIES
• 11.3 NATURAL LANGUAGE PROCESSING
  • 11.3.1 ABUNDANCE OF UNSTRUCTURED DATA IN CLINICAL RESEARCH TO PROPEL GROWTH IN TRIAL MANAGEMENT
• 11.4 COMPUTER VISION
  • 11.4.1 RISING NEED FOR REPRODUCIBLE ANALYSIS IN CLINICAL ENDPOINTS TO DRIVE MARKET
• 11.5 ROBOTIC PROCESS AUTOMATION
  • 11.5.1 ROBOTIC PROCESS AUTOMATION TO ENHANCE OPERATIONAL EFFICIENCY BY AUTOMATING ADMINISTRATIVE WORKFLOWS
• 11.6 OTHER TECHNOLOGIES

12 AI IN CLINICAL TRIALS MARKET, BY APPLICATION

• 12.1 INTRODUCTION
• 12.2 BIOMARKERS
  • 12.2.1 INCREASING INVESTMENTS IN AI-BASED INNOVATION TO AID DEVELOPMENT OF PERSONALIZED HEALTHCARE SOLUTIONS
• 12.3 CELL & GENE THERAPY
  • 12.3.1 HIGH PREVALENCE OF GENETIC DISORDERS AND TECHNOLOGICAL ADVANCEMENTS IN CAR-T THERAPIES TO DRIVE GROWTH
• 12.4 REGENERATIVE MEDICINES
  • 12.4.1 INCREASED NEED FOR PRECISE MONITORING AND ADVANCEMENTS IN STEM CELL RESEARCH TO SPUR MARKET GROWTH
• 12.5 MEDICAL DEVICES & DIAGNOSTICS
  • 12.5.1 NEED FOR REAL-TIME MONITORING AND REMOTE DATA ACQUISITION DURING TRIALS TO ACCELERATE MARKET GROWTH

13 AI IN CLINICAL TRIALS MARKET, BY END USER

• 13.1 INTRODUCTION
• 13.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
  • 13.2.1 HIGH R&D INVESTMENTS AND INCREASED REGULATORY COMPLIANCE TO AUGMENT MARKET GROWTH
• 13.3 RESEARCH INSTITUTES & LABORATORIES
  • 13.3.1 INCREASED GOVERNMENT GRANTS AND COLLABORATIONS WITH PHARMACEUTICAL COMPANIES TO SUPPORT MARKET GROWTH
• 13.4 HEALTHCARE PROVIDERS
  • 13.4.1 ADVANCEMENTS IN PRECISION MEDICINES AND NEED FOR REAL-WORLD EVIDENCE IN CLINICAL RESEARCH TO DRIVE MARKET
• 13.5 CONTRACT RESEARCH ORGANIZATIONS
  • 13.5.1 RISING DEMAND FOR OUTSOURCING CLINICAL TRIAL ACTIVITIES BY PHARMACEUTICAL COMPANIES TO AID MARKET GROWTH
• 13.6 MEDICAL DEVICE MANUFACTURERS
  • 13.6.1 DEMAND FOR AI-DRIVEN DIAGNOSTICS AND MONITORING DEVICES FOR REMOTE CARE TO PROPEL MARKET GROWTH

14 AI IN CLINICAL TRIALS MARKET, BY REGION

• 14.1 INTRODUCTION
• 14.2 NORTH AMERICA
  • 14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 14.2.2 US
    • 14.2.2.1 US to dominate North American AI in clinical trials market during study period
  • 14.2.3 CANADA
    • 14.2.3.1 Rising need for data standardization and increasing health expenditure to support market growth
• 14.3 EUROPE
  • 14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 14.3.2 UK
    • 14.3.2.1 High R&D investment by government organizations to augment market growth
  • 14.3.3 GERMANY
    • 14.3.3.1 Increased focus on research activities and strategic developments by pharma & biotech companies to drive market
  • 14.3.4 FRANCE
    • 14.3.4.1 Strong government support and focus on domestic drug research to propel market growth
  • 14.3.5 ITALY
    • 14.3.5.1 Increased R&D investments from pharmaceutical companies and reduced time for drug approvals to fuel market growth
  • 14.3.6 SPAIN
    • 14.3.6.1 Increased technological investments by private organizations and integrated healthcare systems to spur market growth
  • 14.3.7 REST OF EUROPE
• 14.4 ASIA PACIFIC
  • 14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 14.4.2 JAPAN
    • 14.4.2.1 Well-established clinical trial infrastructure and advanced biomedical research to support market growth
  • 14.4.3 CHINA
    • 14.4.3.1 Low cost of clinical trials and availability of treatment-naive population to propel market growth
  • 14.4.4 INDIA
    • 14.4.4.1 Favorable government policies and high R&D expenditure by Indian pharmaceutical companies to spur market growth
  • 14.4.5 REST OF ASIA PACIFIC
• 14.5 LATIN AMERICA
  • 14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 14.5.2 BRAZIL
    • 14.5.2.1 Increasing governmental support for innovation and growing biotechnology sector to drive market
  • 14.5.3 MEXICO
    • 14.5.3.1 Strong technological and research capabilities in AI applications to fuel market growth
  • 14.5.4 REST OF LATIN AMERICA
• 14.6 MIDDLE EAST & AFRICA
  • 14.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 14.6.2 GCC COUNTRIES
    • 14.6.2.1 Technological innovations and focus on precision medicines to augment market growth
  • 14.6.3 REST OF MIDDLE EAST & AFRICA

15 COMPETITIVE LANDSCAPE

• 15.1 INTRODUCTION
• 15.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN AI IN CLINICAL TRIALS MARKET
• 15.3 REVENUE ANALYSIS, 2019-2023
• 15.4 MARKET SHARE ANALYSIS, 2023
  • 15.4.1 RANKING OF KEY MARKET PLAYERS
• 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 15.5.1 STARS
  • 15.5.2 EMERGING LEADERS
  • 15.5.3 PERVASIVE PLAYERS
  • 15.5.4 PARTICIPANTS
  • 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 15.5.5.1 Company footprint
    • 15.5.5.2 Region footprint
    • 15.5.5.3 Offering footprint
    • 15.5.5.4 Function footprint
    • 15.5.5.5 End-user footprint
• 15.6 COMPANY EVALUATION QUADRANT: STARTUP/SMES, 2023
  • 15.6.1 PROGRESSIVE COMPANIES
  • 15.6.2 RESPONSIVE COMPANIES
  • 15.6.3 DYNAMIC COMPANIES
  • 15.6.4 STARTING BLOCKS
  • 15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 15.7 COMPANY EVALUATION & FINANCIAL METRICS
• 15.8 BRAND/PRODUCT COMPARISON
• 15.9 COMPETITIVE SCENARIO
  • 15.9.1 PRODUCT/SERVICE/SOLUTION LAUNCHES
  • 15.9.2 DEALS
  • 15.9.3 OTHER DEVELOPMENTS

16 COMPANY PROFILES

• 16.1 KEY PLAYERS
  • 16.1.1 IQVIA INC.
    • 16.1.1.1 Products/Services/Solutions offered
    • 16.1.1.2 Recent developments
      • 16.1.1.2.1 Solution launches
      • 16.1.1.2.2 Deals
    • 16.1.1.3 MnM view
      • 16.1.1.3.1 Right to win
      • 16.1.1.3.2 Strategic choices
      • 16.1.1.3.3 Weaknesses & competitive threats
  • 16.1.2 DASSAULT SYSTEMES (MEDIDATA)
    • 16.1.2.1 Business overview
    • 16.1.2.2 Products/Services/Solutions offered
    • 16.1.2.3 Recent developments
      • 16.1.2.3.1 Solution launches
      • 16.1.2.3.2 Deals
    • 16.1.2.4 MnM view
      • 16.1.2.4.1 Right to win
      • 16.1.2.4.2 Strategic choices
      • 16.1.2.4.3 Weaknesses & competitive threats
  • 16.1.3 INSILICO MEDICINE
    • 16.1.3.1 Business overview
    • 16.1.3.2 Products/Services/Solutions offered
    • 16.1.3.3 Recent developments
      • 16.1.3.3.1 Other developments
    • 16.1.3.4 MnM view
      • 16.1.3.4.1 Right to win
      • 16.1.3.4.2 Strategic choices
      • 16.1.3.4.3 Weaknesses & competitive threats
  • 16.1.4 TEMPUS AI, INC.
    • 16.1.4.1 Business overview
    • 16.1.4.2 Products/Services/Solutions offered
    • 16.1.4.3 Recent developments
      • 16.1.4.3.1 Solution launches
      • 16.1.4.3.2 Deals
      • 16.1.4.3.3 Other developments
    • 16.1.4.4 MnM view
      • 16.1.4.4.1 Right to win
      • 16.1.4.4.2 Strategic choices
      • 16.1.4.4.3 Weaknesses & competitive threats
  • 16.1.5 NVIDIA CORPORATION
    • 16.1.5.1 Business overview
    • 16.1.5.2 Products/Services/Solutions offered
    • 16.1.5.3 Recent developments
      • 16.1.5.3.1 Product and service launches
      • 16.1.5.3.2 Deals
    • 16.1.5.4 MnM view
      • 16.1.5.4.1 Right to win
      • 16.1.5.4.2 Strategic choices
      • 16.1.5.4.3 Weaknesses & competitive threats
  • 16.1.6 SAAMA
    • 16.1.6.1 Business overview
    • 16.1.6.2 Products/Services/Solutions offered
    • 16.1.6.3 Recent developments
      • 16.1.6.3.1 Solution launches
      • 16.1.6.3.2 Deals
  • 16.1.7 PHESI
    • 16.1.7.1 Business overview
    • 16.1.7.2 Products/Services/Solutions offered
    • 16.1.7.3 Recent developments
      • 16.1.7.3.1 Solution launches
      • 16.1.7.3.2 Deals
  • 16.1.8 PATHAI, INC.
    • 16.1.8.1 Business overview
    • 16.1.8.2 Products/Services/Solutions offered
  • 16.1.9 UNLEARN.AI, INC.
    • 16.1.9.1 Business overview
    • 16.1.9.2 Products/Services/Solutions offered
    • 16.1.9.3 Recent developments
      • 16.1.9.3.1 Solution launches
      • 16.1.9.3.2 Deals
      • 16.1.9.3.3 Other developments
  • 16.1.10 DEEP6.AI
    • 16.1.10.1 Business overview
    • 16.1.10.2 Products/Services/Solutions offered
    • 16.1.10.3 Recent developments
      • 16.1.10.3.1 Solution launch
      • 16.1.10.3.2 Deals
  • 16.1.11 MICROSOFT
    • 16.1.11.1 Business overview
    • 16.1.11.2 Products/Services/Solutions offered
    • 16.1.11.3 Recent developments
  • 16.1.12 IBM
    • 16.1.12.1 Business overview
    • 16.1.12.2 Products/Services/Solutions offered
    • 16.1.12.3 Recent developments
      • 16.1.12.3.1 Deals
  • 16.1.13 CONCERTAI
    • 16.1.13.1 Business overview
    • 16.1.13.2 Products/Services/Solutions offered
    • 16.1.13.3 Recent developments
      • 16.1.13.3.1 Solution launches
      • 16.1.13.3.2 Deals
      • 16.1.13.3.3 Other developments
  • 16.1.14 AICURE
    • 16.1.14.1 Business overview
    • 16.1.14.2 Products/Services/Solutions offered
    • 16.1.14.3 Recent developments
      • 16.1.14.3.1 Service launches
      • 16.1.14.3.2 Deals
  • 16.1.15 MEDIAN TECHNOLOGIES
    • 16.1.15.1 Business overview
    • 16.1.15.2 Products/Services/Solutions offered
  • 16.1.16 LANTERN PHARMA INC.
    • 16.1.16.1 Business overview
    • 16.1.16.2 Products/Services/Solutions offered
    • 16.1.16.3 Recent developments
      • 16.1.16.3.1 Deals
  • 16.1.17 CITELINE, A NORSTELLA COMPANY
    • 16.1.17.1 Business overview
    • 16.1.17.2 Products/Services/Solutions offered
    • 16.1.17.3 Recent developments
      • 16.1.17.3.1 Solution launches
      • 16.1.17.3.2 Deals
  • 16.1.18 TRINETX, LLC
    • 16.1.18.1 Business overview
    • 16.1.18.2 Products/Services/Solutions offered
    • 16.1.18.3 Recent developments
      • 16.1.18.3.1 Deals
• 16.2 OTHER PLAYERS
  • 16.2.1 REVIVEMED INC.
  • 16.2.2 EURETOS
  • 16.2.3 VERISIM LIFE
  • 16.2.4 TRIOMICS
  • 16.2.5 ARDIGEN
  • 16.2.6 QUANTHEALTH LTD.
  • 16.2.7 DEEP GENOMICS

17 APPENDIX

• 17.1 DISCUSSION GUIDE
• 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 17.3 CUSTOMIZATION OPTIONS
• 17.4 RELATED REPORTS
• 17.5 AUTHOR DETAILS

List of Tables

• TABLE 1 AI IN CLINICAL TRIALS MARKET: INCLUSIONS & EXCLUSIONS
• TABLE 2 AI IN CLINICAL TRIALS MARKET: STUDY ASSUMPTIONS
• TABLE 3 AI IN CLINICAL TRIALS MARKET: RISK ASSESSMENT
• TABLE 4 AI IN CLINICAL TRIALS MARKET: IMPACT ANALYSIS
• TABLE 5 CASE STUDY 1: AI-POWERED APPROACH TO OVERCOME CHALLENGES IN IPF DRUG DEVELOPMENT
• TABLE 6 CASE STUDY 2: REVOLUTIONIZING CLINICAL TRIAL ENROLLMENT WITH ADVANCED MATCHING NETWORKS
• TABLE 7 CASE STUDY 3: BREAKTHROUGH IN CANCER TREATMENT WITH FDA APPROVAL FOR PHASE 1 TRIALS
• TABLE 8 AI IN CLINICAL TRIALS MARKET: PORTER'S FIVE FORCES
• TABLE 9 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS (%)
• TABLE 10 KEY BUYING CRITERIA FOR TOP THREE END USERS
• TABLE 11 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 12 NORTH AMERICA: REGULATORY FRAMEWORK
• TABLE 13 EUROPE: REGULATORY FRAMEWORK
• TABLE 14 ASIA PACIFIC: REGULATORY FRAMEWORK
• TABLE 15 MIDDLE EAST & AFRICA: REGULATORY FRAMEWORK
• TABLE 16 LATIN AMERICA: REGULATORY FRAMEWORK
• TABLE 17 AI IN CLINICAL TRIALS MARKET: LIST OF PATENTS/PATENT APPLICATIONS, 2023-2024
• TABLE 18 INDICATIVE PRICE OF KEY AI SOFTWARE, BY KEY PLAYER, 2023
• TABLE 19 INDICATIVE PRICE TREND OF KEY AI SOFTWARE, BY REGION, 2022-2024
• TABLE 20 AI IN CLINICAL TRIALS MARKET: KEY CONFERENCES & EVENTS, JANUARY 2024-DECEMBER 2025
• TABLE 21 AI IN CLINICAL TRIALS MARKET: UNMET NEEDS
• TABLE 22 AI IN CLINICAL TRIALS MARKET: END-USER EXPECTATIONS
• TABLE 23 AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
• TABLE 24 AI IN CLINICAL TRIALS MARKET FOR END-TO-END SOLUTIONS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 25 AI IN CLINICAL TRIALS MARKET FOR NICHE SOLUTIONS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 26 AI IN CLINICAL TRIALS MARKET FOR TECHNOLOGY PROVIDERS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 27 AI IN CLINICAL TRIALS MARKET FOR SERVICES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 28 CONSULTING SERVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 29 IMPLEMENTATION SERVICES & OUTGOING IT SUPPORT MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 30 TRAINING & EDUCATION SERVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 31 POST-SALES & MAINTENANCE SERVICES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 32 AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
• TABLE 33 AI IN CLINICAL TRIALS MARKET FOR PATIENT RECRUITMENT, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 34 AI IN CLINICAL TRIALS MARKET FOR PATIENT RECRUITMENT, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 35 PATIENT IDENTIFICATION & SCREENING MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 36 PATIENT ENGAGEMENT & RETENTION MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 37 SITE OPTIMIZATION MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 38 AI IN CLINICAL TRIALS MARKET FOR TRIAL DESIGN OPTIMIZATION, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 39 AI IN CLINICAL TRIALS MARKET FOR TRIAL DESIGN OPTIMIZATION, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 40 AI IN CLINICAL TRIALS MARKET FOR WORKFLOW MANAGEMENT, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 41 AI IN CLINICAL TRIALS MARKET FOR PREDICTIVE MODELING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 42 AI IN CLINICAL TRIALS MARKET FOR RISK MANAGEMENT, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 43 AI IN CLINICAL TRIALS MARKET FOR DATA MANAGEMENT & QUALITY CONTROL, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 44 AI IN CLINICAL TRIALS MARKET FOR ADVERSE EVENT PREDICTION & DETECTION, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 45 AI IN CLINICAL TRIALS MARKET FOR DRUG REPURPOSING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 46 AI IN CLINICAL TRIALS MARKET FOR REGULATORY COMPLIANCE, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 47 AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
• TABLE 48 AI IN PHASE 1 CLINICAL TRIALS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 49 AI IN PHASE II CLINICAL TRIALS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 50 AI IN PHASE III CLINICAL TRIALS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 51 AI IN PHASE IV CLINICAL TRIALS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 52 AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
• TABLE 53 AI IN CLINICAL TRIALS MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 54 AI IN CLINICAL TRIALS MARKET FOR CLOUD-BASED SOLUTIONS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 55 PUBLIC CLOUD-BASED SOLUTIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 56 PRIVATE CLOUD-BASED SOLUTIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 57 MULTI CLOUD-BASED SOLUTIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 58 HYBRID CLOUD-BASED SOLUTIONS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 59 AI IN CLINICAL TRIALS MARKET FOR ON-PREMISES SOLUTIONS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 60 AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
• TABLE 61 AI IN CLINICAL TRIALS MARKET FOR ONCOLOGY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 62 AI IN CLINICAL TRIALS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 63 AI IN CLINICAL TRIALS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 64 AI IN CLINICAL TRIALS MARKET FOR METABOLIC DISEASES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 65 AI IN CLINICAL TRIALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 66 AI IN CLINICAL TRIALS MARKET FOR IMMUNOLOGY DISEASES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 67 AI IN CLINICAL TRIALS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 68 AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 69 AI IN CLINICAL TRIALS MARKET FOR MACHINE LEARNING, BY TYPE, 2022-2030 (USD MILLION)
• TABLE 70 AI IN CLINICAL TRIALS MARKET FOR MACHINE LEARNING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 71 DEEP LEARNING MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 72 SUPERVISED LEARNING MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 73 UNSUPERVISED LEARNING MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 74 REINFORCEMENT LEARNING MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 75 OTHER MACHINE LEARNING TECHNOLOGIES MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 76 AI IN CLINICAL TRIALS MARKET FOR NATURAL LANGUAGE PROCESSING, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 77 AI IN CLINICAL TRIALS MARKET FOR COMPUTER VISION, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 78 AI IN CLINICAL TRIALS MARKET FOR ROBOTIC PROCESS AUTOMATION, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 79 AI IN CLINICAL TRIALS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 80 AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 81 AI IN CLINICAL TRIALS MARKET FOR BIOMARKERS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 82 AI IN CLINICAL TRIALS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 83 AI IN CLINICAL TRIALS MARKET FOR REGENERATIVE MEDICINES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 84 AI IN CLINICAL TRIALS MARKET FOR MEDICAL DEVICES & DIAGNOSTICS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 85 AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 86 AI IN CLINICAL TRIALS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 87 AI IN CLINICAL TRIALS MARKET FOR RESEARCH INSTITUTES & LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 88 AI IN CLINICAL TRIALS MARKET FOR HEALTHCARE PROVIDERS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 89 RECENT ACQUISITIONS /COLLABORATIONS WITH CONTRACT RESEARCH ORGANIZATIONS
• TABLE 90 AI IN CLINICAL TRIALS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 91 AI IN CLINICAL TRIALS MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 92 AI IN CLINICAL TRIALS MARKET, BY REGION, 2022-2030 (USD MILLION)
• TABLE 93 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 94 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
• TABLE 95 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
• TABLE 96 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
• TABLE 97 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
• TABLE 98 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 99 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 100 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
• TABLE 101 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 102 US: INDICATIVE LIST OF STRATEGIC DEVELOPMENTS
• TABLE 103 US: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
• TABLE 104 US: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
• TABLE 105 US: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
• TABLE 106 US: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
• TABLE 107 US: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 108 US: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 109 US: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
• TABLE 110 US: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 111 CANADA: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
• TABLE 112 CANADA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
• TABLE 113 CANADA: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
• TABLE 114 CANADA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
• TABLE 115 CANADA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 116 CANADA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 117 CANADA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
• TABLE 118 CANADA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 119 EUROPE: AI IN CLINICAL TRIALS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 120 EUROPE: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
• TABLE 121 EUROPE: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
• TABLE 122 EUROPE: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
• TABLE 123 EUROPE: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
• TABLE 124 EUROPE: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 125 EUROPE: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 126 EUROPE: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
• TABLE 127 EUROPE: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 128 UK: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
• TABLE 129 UK: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
• TABLE 130 UK: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
• TABLE 131 UK: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
• TABLE 132 UK: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 133 UK: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 134 UK: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
• TABLE 135 UK: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 136 GERMANY: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
• TABLE 137 GERMANY: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
• TABLE 138 GERMANY: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
• TABLE 139 GERMANY: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
• TABLE 140 GERMANY: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 141 GERMANY: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 142 GERMANY: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
• TABLE 143 GERMANY: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 144 FRANCE: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
• TABLE 145 FRANCE: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
• TABLE 146 FRANCE: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
• TABLE 147 FRANCE: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
• TABLE 148 FRANCE: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 149 FRANCE: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 150 FRANCE: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
• TABLE 151 FRANCE: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 152 ITALY: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
• TABLE 153 ITALY: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
• TABLE 154 ITALY: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
• TABLE 155 ITALY: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
• TABLE 156 ITALY: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 157 ITALY: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 158 ITALY: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
• TABLE 159 ITALY: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 160 SPAIN: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
• TABLE 161 SPAIN: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
• TABLE 162 SPAIN: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
• TABLE 163 SPAIN: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
• TABLE 164 SPAIN: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 165 SPAIN: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 166 SPAIN: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
• TABLE 167 SPAIN: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 168 REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
• TABLE 169 REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
• TABLE 170 REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
• TABLE 171 REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
• TABLE 172 REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 173 REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 174 REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
• TABLE 175 REST OF EUROPE: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 176 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 177 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
• TABLE 178 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
• TABLE 179 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
• TABLE 180 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
• TABLE 181 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 182 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 183 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
• TABLE 184 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 185 JAPAN: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
• TABLE 186 JAPAN: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
• TABLE 187 JAPAN: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
• TABLE 188 JAPAN: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
• TABLE 189 JAPAN: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 190 JAPAN: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 191 JAPAN: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
• TABLE 192 JAPAN: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 193 CHINA: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
• TABLE 194 CHINA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
• TABLE 195 CHINA: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
• TABLE 196 CHINA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
• TABLE 197 CHINA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 198 CHINA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 199 CHINA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
• TABLE 200 CHINA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 201 INDIA: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
• TABLE 202 INDIA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
• TABLE 203 INDIA: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
• TABLE 204 INDIA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
• TABLE 205 INDIA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 206 INDIA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 207 INDIA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
• TABLE 208 INDIA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 209 REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
• TABLE 210 REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
• TABLE 211 REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
• TABLE 212 REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
• TABLE 213 REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 214 REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 215 REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
• TABLE 216 REST OF ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 217 LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
• TABLE 218 LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
• TABLE 219 LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
• TABLE 220 LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
• TABLE 221 LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
• TABLE 222 LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 223 LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 224 LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
• TABLE 225 LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 226 BRAZIL: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
• TABLE 227 BRAZIL: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
• TABLE 228 BRAZIL: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
• TABLE 229 BRAZIL: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
• TABLE 230 BRAZIL: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 231 BRAZIL: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 232 BRAZIL: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
• TABLE 233 BRAZIL: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 234 MEXICO: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
• TABLE 235 MEXICO: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
• TABLE 236 MEXICO: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
• TABLE 237 MEXICO: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
• TABLE 238 MEXICO: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 239 MEXICO: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 240 MEXICO: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
• TABLE 241 MEXICO: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 242 REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
• TABLE 243 REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
• TABLE 244 REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
• TABLE 245 REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
• TABLE 246 REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 247 REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 248 REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
• TABLE 249 REST OF LATIN AMERICA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 250 MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY REGION, 2022-2030 (USD MILLION)
• TABLE 251 MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
• TABLE 252 MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
• TABLE 253 MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
• TABLE 254 MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
• TABLE 255 MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 256 MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 257 MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
• TABLE 258 MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 259 GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
• TABLE 260 GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
• TABLE 261 GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
• TABLE 262 GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
• TABLE 263 GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 264 GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 265 GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
• TABLE 266 GCC COUNTRIES: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 267 REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2022-2030 (USD MILLION)
• TABLE 268 REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2022-2030 (USD MILLION)
• TABLE 269 REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2022-2030 (USD MILLION)
• TABLE 270 REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY PHASE, 2022-2030 (USD MILLION)
• TABLE 271 REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2022-2030 (USD MILLION)
• TABLE 272 REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
• TABLE 273 REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2022-2030 (USD MILLION)
• TABLE 274 REST OF MIDDLE EAST & AFRICA: AI IN CLINICAL TRIALS MARKET, BY END USER, 2022-2030 (USD MILLION)
• TABLE 275 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN AI IN CLINICAL TRIALS MARKET
• TABLE 276 AI IN CLINICAL TRIALS MARKET: DEGREE OF COMPETITION
• TABLE 277 AI IN CLINICAL TRIALS MARKET: REGION FOOTPRINT
• TABLE 278 AI IN CLINICAL TRIALS MARKET: OFFERING FOOTPRINT
• TABLE 279 AI IN CLINICAL TRIALS MARKET: FUNCTION FOOTPRINT
• TABLE 280 AI IN CLINICAL TRIALS MARKET: END-USER FOOTPRINT
• TABLE 281 AI IN CLINICAL TRIALS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
• TABLE 282 AI IN CLINICAL TRIALS MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
• TABLE 283 AI IN CLINICAL TRIALS MARKET: PRODUCT/SERVICE/SOLUTION LAUNCHES, JANUARY 2021-NOVEMBER 2024
• TABLE 284 AI IN CLINICAL TRIALS MARKET: DEALS, JANUARY 2021- NOVEMBER 2024
• TABLE 285 AI IN CLINICAL TRIALS MARKET: OTHER DEVELOPMENTS, JANUARY 2021- NOVEMBER 2024
• TABLE 286 IQVIA INC.: COMPANY OVERVIEW
• TABLE 287 IQVIA INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 288 IQVIA INC.: SOLUTION LAUNCHES, JANUARY 2021-NOVEMBER 2024
• TABLE 289 IQVIA INC.: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 290 DASSAULT SYSTEMES (MEDIDATA): COMPANY OVERVIEW
• TABLE 291 DASSAULT SYSTEMES (MEDIDATA): PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 292 DASSAULT SYSTEMES (MEDIDATA): SOLUTION LAUNCHES, JANUARY 2021- NOVEMBER 2024
• TABLE 293 DASSAULT SYSTEMES (MEDIDATA): DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 294 INSILICO MEDICINE: COMPANY OVERVIEW
• TABLE 295 INSILICO MEDICINE: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 296 INSILICO MEDICINE: OTHER DEVELOPMENTS, JANUARY 2021-NOVEMBER 2024
• TABLE 297 TEMPUS AI, INC.: COMPANY OVERVIEW
• TABLE 298 TEMPUS AI, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 299 TEMPUS AI, INC.: SOLUTION LAUNCHES, JANUARY 2021-NOVEMBER 2024
• TABLE 300 TEMPUS AI, INC.: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 301 TEMPUS AI, INC.: OTHER DEVELOPMENTS, JANUARY 2021-NOVEMBER 2024
• TABLE 302 NVIDIA CORPORATION: COMPANY OVERVIEW
• TABLE 303 NVIDIA CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 304 NVIDIA CORPORATION: PRODUCT AND SERVICE LAUNCHES, JANUARY 2021- NOVEMBER 2024
• TABLE 305 NVIDIA CORPORATION: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 306 SAAMA: COMPANY OVERVIEW
• TABLE 307 SAAMA: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 308 SAAMA: SOLUTION LAUNCHES, JANUARY 2021-NOVEMBER 2024
• TABLE 309 SAAMA.: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 310 PHESI: COMPANY OVERVIEW
• TABLE 311 PHESI: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 312 PHESI: SOLUTION LAUNCHES, JANUARY 2021-NOVEMBER 2024
• TABLE 313 PHESI: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 314 PATHAI, INC.: COMPANY OVERVIEW
• TABLE 315 PATHAI, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 316 UNLEARN.AI, INC.: COMPANY OVERVIEW
• TABLE 317 UNLEARN.AI, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 318 UNLEARN.AI, INC.: SOLUTION LAUNCHES, JANUARY 2021-NOVEMBER 2024
• TABLE 319 UNLEARN.AI, INC.: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 320 UNLEARN.AI, INC.: OTHER DEVELOPMENTS, JANUARY 2021-NOVEMBER 2024
• TABLE 321 DEEP6.AI: COMPANY OVERVIEW
• TABLE 322 DEEP6.AI: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 323 DEEP6.AI: SOLUTION LAUNCH, JANUARY 2021-NOVEMBER 2024
• TABLE 324 DEEP6.AI: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 325 MICROSOFT: COMPANY OVERVIEW
• TABLE 326 MICROSOFT: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 327 MICROSOFT CORPORATION: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 328 IBM: COMPANY OVERVIEW
• TABLE 329 IBM: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 330 IBM: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 331 CONCERTAI: COMPANY OVERVIEW
• TABLE 332 CONCERTAI: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 333 CONCERTAI: SOLUTION LAUNCHES, JANUARY 2021-NOVEMBER 2024
• TABLE 334 CONCERTAI: DEALS, JANUARY 2021- NOVEMBER 2024
• TABLE 335 CONCERTAI: OTHER DEVELOPMENTS, JANUARY 2021- NOVEMBER 2024
• TABLE 336 AICURE: COMPANY OVERVIEW
• TABLE 337 AICURE: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 338 AICURE: SERVICE LAUNCHES, JANUARY 2021-NOVEMBER 2024
• TABLE 339 AICURE: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 340 MEDIAN TECHNOLOGIES: COMPANY OVERVIEW
• TABLE 341 MEDIAN TECHNOLOGIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 342 LANTERN PHARMA INC.: COMPANY OVERVIEW
• TABLE 343 LANTERN PHARMA INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 344 LANTERN PHARMA INC.: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 345 CITELINE, A NORSTELLA COMPANY: COMPANY OVERVIEW
• TABLE 346 CITELINE, A NORSTELLA COMPANY: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 347 CITELINE, A NORSTELLA COMPANY: SOLUTION LAUNCHES, JANUARY 2021- NOVEMBER 2024
• TABLE 348 CITELINE, A NORSTELLA COMPANY: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 349 TRINETX, LLC: COMPANY OVERVIEW
• TABLE 350 TRINETX, LLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
• TABLE 351 TRINETX, LLC: DEALS, JANUARY 2021-NOVEMBER 2024
• TABLE 352 REVIVEMED INC.: COMPANY OVERVIEW
• TABLE 353 EURETOS: COMPANY OVERVIEW
• TABLE 354 VERISIM LIFE: COMPANY OVERVIEW
• TABLE 355 TRIOMICS: COMPANY OVERVIEW
• TABLE 356 ARDIGEN: COMPANY OVERVIEW
• TABLE 357 QUANTHEALTH LTD.: COMPANY OVERVIEW
• TABLE 358 DEEP GENOMICS: COMPANY OVERVIEW

List of Figures

• FIGURE 1 AI IN CLINICAL TRIALS MARKET: SEGMENTS CONSIDERED
• FIGURE 2 AI IN CLINICAL TRIALS MARKET: YEARS CONSIDERED
• FIGURE 3 AI IN CLINICAL TRIALS MARKET: RESEARCH DESIGN
• FIGURE 4 AI IN CLINICAL TRIALS MARKET: KEY DATA FROM SECONDARY SOURCES
• FIGURE 5 AI IN CLINICAL TRIALS MARKET: KEY PRIMARY SOURCES
• FIGURE 6 AI IN CLINICAL TRIALS MARKET: KEY DATA FROM PRIMARY SOURCES
• FIGURE 7 AI IN CLINICAL TRIALS MARKET: KEY INSIGHTS FROM PRIMARIES
• FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
• FIGURE 9 MARKET SIZE ESTIMATION: SUPPLY-SIDE REVENUE SHARE ANALYSIS
• FIGURE 10 AI IN CLINICAL TRIALS MARKET: TOP-DOWN APPROACH
• FIGURE 11 AI IN CLINICAL TRIALS MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 12 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
• FIGURE 13 AI IN CLINICAL TRIALS MARKET: DATA TRIANGULATION
• FIGURE 14 AI IN CLINICAL TRIALS MARKET, BY OFFERING, 2024 VS. 2030 (USD MILLION)
• FIGURE 15 AI IN CLINICAL TRIALS MARKET, BY FUNCTION, 2024 VS. 2030 (USD MILLION)
• FIGURE 16 AI IN CLINICAL TRIALS MARKET, BY DEPLOYMENT MODE, 2024 VS. 2030 (USD MILLION)
• FIGURE 17 AI IN CLINICAL TRIALS MARKET, BY PHASE, 2024 VS. 2030 (USD MILLION)
• FIGURE 18 AI IN CLINICAL TRIALS MARKET, BY APPLICATION, 2024 VS. 2030 (USD MILLION)
• FIGURE 19 AI IN CLINICAL TRIALS MARKET, BY TECHNOLOGY, 2024 VS. 2030 (USD MILLION)
• FIGURE 20 AI IN CLINICAL TRIALS MARKET, BY INDICATION, 2024 VS. 2030 (USD MILLION)
• FIGURE 21 AI IN CLINICAL TRIALS MARKET, BY END USER, 2024 VS. 2030 (USD MILLION)
• FIGURE 22 AI IN CLINICAL TRIALS MARKET: REGIONAL SNAPSHOT
• FIGURE 23 NEED FOR DATA STANDARDIZATION AND FAVORABLE GOVERNMENT POLICIES TO DRIVE MARKET
• FIGURE 24 NORTH AMERICA TO DOMINATE AI IN CLINICAL TRIALS MARKET DURING FORECAST PERIOD
• FIGURE 25 US AND PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2023
• FIGURE 26 UK TO REGISTER HIGHEST GROWTH RATE DURING STUDY PERIOD
• FIGURE 27 DEVELOPED MARKETS TO REGISTER HIGHER GROWTH RATES FROM 2024 TO 2029
• FIGURE 28 AI IN CLINICAL TRIALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 29 APPROVAL OF PERSONALIZED MEDICINES BY US FDA, 2015-2023
• FIGURE 30 HEALTHCARE SECURITY BREACHES OF 500+ RECORDS (2009-2023)
• FIGURE 31 AI IN CLINICAL TRIALS MARKET: ECOSYSTEM ANALYSIS
• FIGURE 32 AI IN CLINICAL TRIALS MARKET: VALUE CHAIN ANALYSIS
• FIGURE 33 AI IN CLINICAL TRIALS MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 34 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS
• FIGURE 35 KEY BUYING CRITERIA FOR TOP THREE END USERS
• FIGURE 36 PATENT PUBLICATION TRENDS IN AI IN CLINICAL TRIALS MARKET, 2015-2024
• FIGURE 37 TOP APPLICANTS/OWNERS OF PATENTS AND NUMBER OF PATENTS GRANTED, JANUARY 2015-NOVEMBER 2024
• FIGURE 38 AI IN CLINICAL TRIALS MARKET: TRENDS AND DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
• FIGURE 39 AI IN CLINICAL TRIALS MARKET: FUNDING AND NUMBER OF DEALS, 2022-2024
• FIGURE 40 IMPACT OF AI/GEN AI ON AI-BASED CLINICAL TRIAL SOLUTIONS
• FIGURE 41 IMPACT OF GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
• FIGURE 42 NORTH AMERICA: AI IN CLINICAL TRIALS MARKET SNAPSHOT
• FIGURE 43 ASIA PACIFIC: AI IN CLINICAL TRIALS MARKET SNAPSHOT
• FIGURE 44 REVENUE ANALYSIS OF KEY PLAYERS IN AI IN CLINICAL TRIALS MARKET, 2019-2023 (USD BILLION)
• FIGURE 45 MARKET SHARE ANALYSIS IN AI IN CLINICAL TRIALS MARKET (2023)
• FIGURE 46 RANKING OF KEY PLAYERS IN AI IN CLINICAL TRIALS MARKET (2023)
• FIGURE 47 AI IN CLINICAL TRIALS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
• FIGURE 48 AI IN CLINICAL TRIALS MARKET: COMPANY FOOTPRINT
• FIGURE 49 AI IN CLINICAL TRIALS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
• FIGURE 50 EV/EBITDA OF KEY VENDORS
• FIGURE 51 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF AI IN CLINICAL TRIAL KEY VENDORS
• FIGURE 52 AI IN CLINICAL TRIALS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
• FIGURE 53 IQVIA INC.: COMPANY SNAPSHOT
• FIGURE 54 DASSAULT SYSTEMES (MEDIDATA): COMPANY SNAPSHOT
• FIGURE 55 NVIDIA CORPORATION: COMPANY SNAPSHOT
• FIGURE 56 MICROSOFT: COMPANY SNAPSHOT
• FIGURE 57 IBM: COMPANY SNAPSHOT
• FIGURE 58 MEDIAN TECHNOLOGIES: COMPANY SNAPSHOT